Differential glucose consumption and protein cargo of fat-released exosomes, after semaglutide or/and insulin treatment were analyzed by enzymatic and TripleTOF, respectively
Sometimes it can be very discouraging to achieve weight loss, yet still have to contend with excess skin
Repurposing of long-acting FDA-approved GLP-1 receptor agonists such as semaglutide, the dual GLP-1/gastric inhibitory polypeptide (GIP) receptor agonist tirzepatide, and the triple-agonist retatrutide which additionally targets glucagon receptors and is currently in clinical trials for obesity, may offer a promising strategy treating AUD
By integrating signaling, structural, and migration-focused research pathways into a single complex, it provides a powerful tool for exploring how tissues repair, regenerate, and adapt at the cellular level